



# FINANCIAL TEAR SHEET

## CORPORATE PROFILE

At PRA Health Sciences, we work side-by-side with our clients, to move drug discovery forward, and to help them develop life-saving and life-improving drugs. For more than 30 years, we've been helping to bring to market everything from niche treatments and therapies to blockbuster drugs. Providing comprehensive Phase I-IV biopharmaceutical drug development in over 20 countries, we are dedicated to being innovative, and to delivering unmatched scientific expertise that improves the drug development process.

We help change people's lives for the better every single day. It's what we are passionate about.

## STOCK QUOTE & CHART

PRAH (Common Stock)	
Exchange	NASDAQ GS (US Dollar)
Financial Status Indicator	C
Price	\$92.89
Change (%)	▲ 0.79 (0.86%)
Volume	120,605
52 Week Low	\$54.12
Market Cap	\$5,886,414,127
Rolling EPS	1.78
PE Ratio	51.6676
Shares Outstanding	63,369,729
Data as of 01/18/18 4:00 p.m. ET	



## NEWS & EVENTS

Date	Title
------	-------

There are currently no events scheduled.

01/16/18	PRA Health Sciences Opens New Salt Lake City Clinic
10/25/17	PRA Health Sciences, Inc. Reports Third Quarter 2017 Results and Updates Full Year 2017 Guidance
10/09/17	PRA Health Sciences to Report Third Quarter 2017 Earnings

## SEC FILINGS

Filing Date	Form
01/18/18	4
01/02/18	4
12/29/17	8-K
12/21/17	8-K

## BOARD OF DIRECTORS

Colin Shannon	Chairman of the Board
Jeffrey T. Barber	Director
Alexander G. Dickinson	Director
Linda S. Grais, M.D.	Director
Max C. Lin	Director
James C. Momtazee	Director
Ali J. Satvat	Director
Matthew P. Young	Director

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)